UBS's $26 billion capital hit may be softer than it first appears
The $26 billion headline capital charge to protect Swiss taxpayers from the risk that UBS Group AG ever fails is worse than anyone expected. And yet UBS's shares jumped as much as 8% on the news Friday – what gives?
It's not that investors now know the costs of Switzerland's beefed-up 'too big to fail' rules, which follow Credit Suisse's 2023 collapse. There's a lot of uncertainty about the draft law's final form. Most likely UBS shares have jumped because investor judge that the final bill will be lower – and because they know it's not due to be paid in full until 2034 at the earliest.
The bank isn't happy. 'UBS strongly disagrees with the extreme increase in capital requirements that has been proposed,' it said in a statement. While it supported most of the changes in principle, the proposed capital increase is 'neither proportionate nor internationally aligned.'
The draft law contains a lot that is sensible and with which UBS and most experts agree. It brings in a Senior Managers' Regime like the UK's, to ensure top executives can be held responsible for everything the bank does and that their pay can be clawed back when it errs. It also gives more power to Swiss regulators to intervene when a bank is being poorly managed: the lack of this ability kept watchdogs on the sidelines during Credit Suisse's long demise. The central bank gets more reliable powers to supply emergency liquidity, too, among other things.
The contentious and costly part for UBS is the demand that it should fully capitalize its foreign subsidiaries, which the government and independent advisors calculated will require as much as $23 billion of extra common equity tier one capital. (The other $3 billion in the headline comes from capital quality changes that affect how banks can account for deferred tax assets and some other intangible assets.)
There's plenty of opportunity for UBS to negotiate this change down during the parliamentary consultation and debate, which will begin later this year. That won't move quickly; the draft law isn't expected to be enacted until the start of 2028. Currently, UBS only needs capital at group level to cover about 60% of the equity value of its foreign units, and only 45% must be common equity; the rest can be additional tier one bonds. In the draft, 100% will need to be common equity.
UBS might be able to negotiate back to a mix of equity and additional tier one, or it might be able to get the coverage level reduced — but ultimately, this is going to deliver the biggest hit. As I've written before, it also makes sense as a policy.
The bank will still have six to eight years from the law being enacted until it must meet whatever the new requirement ends up being, which is why 2034 is the earliest legal deadline. Andrew Coombs, an analyst at Citigroup Inc., said the long lead time meant that billions of dollars in share buybacks forecast for the next three years still looked plausible; the bank said Friday it will continue with this year's payouts as planned.
UBS may argue that bank investors will judge its capital needs against the full target as soon as the law comes into force. That was the case for banks after the 2008 financial crisis, when many were seen as too weak and had to raise capital swiftly. I'm less convinced; analysts and investors are more likely to view it as a technical rather than necessary requirement, giving the bank time to adjust. That doesn't mean UBS's long-term profitability won't be hit, which will affect what its shares are worth. But the bank has ways it can adapt; they just involve tradeoffs.
The most radical reaction would be breaking up its business in some way, such as spinning off its US arm, or partially listing its core Swiss business and moving its headquarters to another country with a more favorable regime. It could also change its holding company-parent bank legal structure in ways that could improve capital efficiency; but that would mean losing some funding cost and tax benefits.
'We expect that UBS might commence work to study the feasibility of strategic actions such as these,' wrote advisers at Alvarez & Marsal in a technical study commissioned by the government to support the draft law. Major surgery on the firm's structure or relocation remain extreme and unlikely in my view, unless UBS gets absolutely nothing out of the consultation process. "UBS remains committed to its diversified business model and its unique regional footprint," the bank said.
UBS could also use more risk transfers or change its loan-led approach in foreign wealth businesses to reduce capital requirements. That would also alter its revenue and returns in good or bad ways.
Even before all this, there are reasons to think the $26 billion headline figure won't last or be as costly as it seems. For one, the bank has plans to repatriate about $5 billion of capital from its overseas units already, which could be done in a way that reduces the carrying value of those subsidiaries and so also cuts their capital requirements at group level, the Alvarez and Marsal report points out. UBS's version of the headline hit included the benefit of this repatriation. On top of that, other changes in the law cut the amount of additional tier one UBS needs by $8 billion, meaning a smaller net increase in total capital requirements, according to Bloomberg Intelligence.
There is plenty to chew on before UBS and its investors can fully digest the implications of this proposed law — but there's a good chance that it all works out to be less painful for the bank than the big headline number suggests.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


India.com
3 hours ago
- India.com
Govt Imposes Anti-Dumping Duties On Vitamin A, Rubber Chemical Imports From China, Japan, EU
New Delhi: The Union government has imposed anti-dumping duties on imports of Vitamin-A Palmitate and insoluble sulphur -- a crucial rubber additive -- on China, Japan, Switzerland, and the European Union (EU). The Ministry of Finance, in a notification on June 6, issued the anti-dumping duties for a period of five years unless it is cancelled or revised. It aims to protect domestic manufacturers from low-priced imports that affect the local industry. The move follows an investigation by the Directorate General of Trade Remedies (DGTR) which revealed that the price of Vitamin-A Palmitate imported by these countries was lower than the normal value. The DGTR also noted 'material injury' to domestic producers of Vitamin-A Palmitate due to large-scale dumping from China, the EU, and Switzerland. The compound, commonly used in small quantities, remains heavily import-dependent in India. While Vitamin-A Palmitate is used in pharmaceuticals, food, and cosmetics, insoluble sulphur plays a key role in the rubber industry, majorly in tyre manufacturing. The anti-dumping duties, effective immediately must be paid in Indian rupees based on the exchange rate. It is expected to prevent unfair trade practices and protect local industries. According to the notification, the duties for Vitamin-A Palmitate, range from $0.87 to $20.87 per kg; The highest duty has been imposed on Chinese exporters other than Shangyu NHU BioChem, which will face a lower rate of $14.95/kg. Swiss producer DSM Nutritional Products will attract a duty of $0.87/kg, while other Swiss exporters will face $8.2/kg. A flat rate of $11.09/kg will apply to imports from the EU, the notification stated. Further, depending on the exporter, the duties on insoluble sulphur will range from $259 to $358 per metric tonne. Chinese imports will face a flat duty of $307/MT. Among Japanese companies, Shikoku Chemicals will be charged $259/MT, while all other Japanese exporters will face the maximum rate of $358/MT, the notification said.


Time of India
8 hours ago
- Time of India
India hits China, Japan and EU with fresh anti-dumping duties on vitamin and rubber chemical imports
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The Indian government has imposed anti-dumping duties on imports of Vitamin-A Palmitate and Insoluble Sulphur from China, Japan, Switzerland and the European Union (EU). The move aims to protect domestic manufacturers from low-priced imports that affect the local duties, which will remain in place for five years, were announced by the finance ministry in a notification issued late on Friday. The decision follows investigations by the Directorate General of Trade Remedies (DGTR), which found that both substances were being exported to India at unfairly low prices, either below cost or under their fair market value, thereby undercutting Indian products are essential to major industries in India. Vitamin-A Palmitate is used in pharmaceuticals, food, and cosmetics, while Insoluble Sulphur plays a key role in tyre manufacturing In its findings, the DGTR said there was 'material injury' to domestic producers of Vitamin-A Palmitate due to large-scale dumping from China, the EU and Switzerland. The compound, commonly used in small quantities, remains heavily import-dependent in duties, which take effect immediately, will range from $0.87 to $20.87 per kilogram. Chinese exporters other than Shangyu NHU BioChem Co. Ltd. will face the highest duty of $20.87/kg. Shangyu NHU BioChem will be subject to a lower duty of $14.95/kg. Swiss company DSM Nutritional Products Ltd. will attract a duty of $0.87/kg, while all other Swiss exporters will face $8.2/kg. Imports from the EU will be charged a flat rate of $11.09/ Vitamin-A Palmitate in the strength of 1.6 MIU/Gm, used in animal feed, has been excluded from the imported $48.6 million worth of Vitamin-A Palmitate in the financial year 2024-25, with most of it sourced from China and Europe, according to commerce ministry duties must be paid in Indian rupees, based on the exchange rate notified by the Revenue Department on the date the bill of entry is a related move, the government also imposed five-year anti-dumping duties on imports of Insoluble Sulphur from China and Japan. This compound is mainly used by tyre manufacturers to improve rubber vulcanisation. DGTR investigations revealed that exporters from both countries had been dumping the product at low prices, affecting the profitability and pricing strength of Indian on the exporter, the duties on Insoluble Sulphur will range from $259 to $358 per metric tonne. Chinese imports will face a flat duty of $307/MT. Among Japanese companies, Shikoku Chemicals will be charged $259/MT, while all other Japanese exporters will face the maximum rate of $358/MT.


Mint
11 hours ago
- Mint
India slaps anti-dumping duties on key chemical imports from China, EU, Japan, and Switzerland
New Delhi: The government has imposed anti-dumping duties on imports of Vitamin-A Palmitate and Insoluble Sulphur from China, Japan, Switzerland and the European Union (EU), aiming to shield domestic manufacturers from low-priced imports that regulators say are hurting local industry. According to a finance ministry notification issued late on Friday, the five-year duties follow investigations by the Directorate General of Trade Remedies (DGTR), which found that both substances were being exported to India at unfairly low prices, below cost or fair market value, and were undercutting Indian producers. These products are critical inputs for sectors such as pharmaceuticals, food, cosmetics and tyre manufacturing. For Vitamin-A Palmitate—used in fortified foods, nutraceuticals and pharma formulations—the DGTR found 'material injury' to domestic producers due to large-scale dumping from China, the EU and Switzerland. The compound, widely used in small dosages, continues to be largely import-dependent in India. Effective immediately, duties will range from $0.87 to $20.87 per kg. The highest duty has been imposed on Chinese exporters other than Shangyu NHU BioChem Co. Ltd., which will face a lower rate of $14.95/kg. Swiss producer DSM Nutritional Products Ltd will attract a duty of $0.87/kg, while other Swiss exporters will face $8.2/kg. A flat rate of $11.09/kg will apply to imports from the EU. Vitamin-A Palmitate in the strength of 1.6 MIU/Gm, used for animal feed, has been excluded from the levy. India imported $48.6 million worth of Vitamin-A Palmitate in FY25, with the bulk of the shipments coming from China and Europe, according to commerce ministry data. While the move comes as a relief for domestic Vitamin-A makers, industry players flagged India's broader dependence on imports for this compound, which is crucial for nutritional and pharmaceutical applications. 'While the anti-dumping duty provides protection to domestic manufacturers of the compound, it could raise input costs for drug makers in the short term, especially those relying on imports from Switzerland and China,' said Yogendra Sharma, a drug manufacturer. 'However, the price impact is expected to be manageable given that Vitamin-A is used in small dosages and accounts for a minor fraction of total formulation cost.' 'With global supply chains realigning, India is now far more proactive in using WTO-compliant instruments to protect its domestic industry. The Vitamin-A Palmitate case is another example of this assertiveness,' said Manish Kr Shubhay, a multidisciplinary dispute resolution expert and Partner at The Percept Law Offices. The anti-dumping duties are payable in Indian currency, based on the exchange rate notified by the Revenue Department on the date of filing the bill of entry. In a related notification, the government also slapped five-year anti-dumping duties on imports of Insoluble Sulphur from China and Japan, used primarily by tyre manufacturers to improve rubber vulcanization. DGTR's investigation found that exporters from both countries were dumping the product at depressed prices, adversely affecting profitability and pricing power of Indian producers. Depending on the exporter, the duties range from $259 to $358 per metric tonne. Chinese imports will face a flat $307/MT levy. Among Japanese exporters, Shikoku Chemicals will be charged $259/MT, while all others will attract the highest rate of $358/MT.